Siobhan Malany's Biography

Siobhan Malany, Director, Translational Biology, Sanford Burnham Prebys Medical Discovery Institute

As Director of Translational Biology at Sanford Burnham Prebys Medical Discovery Institute at Lake Nona (SBP), Dr. Malany’s team has a focus on developing phenotypic screening assays using human iPSC-derived cardiomyocyte and hepatocytes for cardiometabolic and liver disease modeling and toxicological studies. In 2015, she launched the micro-gRx, INC to study the degeneration of human muscle growth and function funded by Space Florida and CASIS. Prior to joining SBP in 2010, she spent eight years in the San Diego biotechnology industry leading receptor pharmacology drug discovery efforts at Neurocine Biosciences and Tanabe Mitsubishi Pharma. Dr. Malany received her PhD in bioorganic chemistry at the University of Iowa and was a postdoctoral fellow in pharmacology at the University of California, San Diego prior to extending her studies at the Max-Planck Institute for Brain Research, Frankfurt, Germany as an Alexander von Humboldt Fellow.

Cardioprotectants: From Phenotype Screening to Pathway Targets

Tuesday, 11 July 2017 at 14:00

Add to Calendar ▼2017-07-11 14:00:002017-07-11 15:00:00Europe/LondonCardioprotectants: From Phenotype Screening to Pathway TargetsStem Cells for Drug Discovery and Toxicity Screening 2017 in Boston, USABoston, USASELECTBIOenquiries@selectbiosciences.com

In the United States alone, approximately one million heart attacks occur per year and only 37% of patients survive one year after suffering a heart attack. A major consequence of myocardial infarction is the loss of cardiomyocytes due to oxidative stress associated with reperfusion. Improving pharmacological therapies that provide protection during cardiac oxidative stress is the focus of significant research and exploratory medicine. We report a chemical biology phenotypic screening approach to identify and validate small molecules that protect human induced pluripotent stem cell cardiomyocytes (hiPSC-CMs) from oxidative stress. Cardioprotective activity of ‘hit’ compounds was confirmed using impedance-based detection of cardiomyocyte monolayer integrity and contractile function. Structure-activity relationship studies led to the identification of a potent class of compounds with 4-(pyridine-2-yl)thiazole scaffold. Examination of gene expression in hiPSC-CMs revealed that the hit compound, designated cardioprotectant 312 (CP-312) induces a marker of the antioxidant response network. CP-312 therefore represents a novel chemical scaffold identified by phenotypic high-throughput screening using hiPSC-CMs that activates the antioxidant defense response and may lead to improved pharmacological cardioprotective therapies.

Add to Calendar ▼2017-07-10 00:00:002017-07-11 00:00:00Europe/LondonStem Cells for Drug Discovery and Toxicity Screening 2017Stem Cells for Drug Discovery and Toxicity Screening 2017 in Boston, USABoston, USASELECTBIOenquiries@selectbiosciences.com

Corporate Sponsors